Activated natural killer cell therapy
- Generic Name
- Activated natural killer cell therapy
- Drug Type
- Biotech
PD-L1 T-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Phase 2
Recruiting
- Conditions
- Head and Neck CancerHead and Neck Squamous Cell CarcinomaMetastatic Head-and-neck Squamous-cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck CancerRecurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Glenn J. Hanna
- Target Recruit Count
- 25
- Registration Number
- NCT06239220
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06061809
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
Phase 2
Recruiting
- Conditions
- Gastroesophageal Junction (GEJ) CancersAdvanced HNSCC
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT04847466
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Phase 2
Active, not recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT04390399
- Locations
- 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
🇺🇸Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸Hoag memorial Presbyterian Hospital, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath